Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.20 --0%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
VISL, GNLN, USDP, More
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
VISL, GNLN, USDP, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of $1.67, versus ($1.86) reported last year. Revenue for the quarter came in at $162.8 million, versus $7.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
- Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
- Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
